Use of #oseltamivir in #lung #transplant recipients with suspected or proven #influenza #infection: a 1-year observational study of outcomes and safety (Antivir Ther., abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Antivir Ther. 2019 Jun 7. doi: 10.3851/IMP3320. [Epub ahead of print]

Use of oseltamivir in lung transplant recipients with suspected or proven influenza infection: a 1-year observational study of outcomes and safety.

Jungo C1, Russmann S2, Benden C1,3, Schuurmans MM1,3,4.

Author information: 1 Divisions of Pulmonology, University Hospital, Zurich, Switzerland. 2 Clinical Pharmacology and Toxicology University Hospital, Zurich, Switzerland. 3 Department of Research and Education, University of Zurich, Zurich, Switzerland. 4 Pulmonology, Department of Internal Medicine, Cantonal Hospital, Winterthur, Switzerland.




Influenza virus infections in lung transplant recipients (LTRs) have an increased risk of unfavorable outcomes. Early initiation of treatment is associated with improved outcomes. In clinical practice, empiric oseltamivir treatment is therefore commonly started prior to diagnostic microbiological confirmation. There is limited data on the patient characteristics, outcomes and safety of this practice. This study investigated outcomes and safety of this preemptive treatment strategy using oseltamivir.


Descriptive analysis of LTRs who received oseltamivir for ≥2 days for suspected influenza infection between 07-2011 and 06-2012. Analyses were based on data from electronic medical records and our standardized LTR database with prospective documentation of clinical information including medication, laboratory and radiological results, outcomes and adverse events.


We included 133 patients with a total of 261 oseltamivir treatment episodes (87.4% as outpatients). Median duration of oseltamivir treatment was 4 days (range 2 to 67), and 98.5% had concomitant antibiotic pharmacotherapy. Indications for oseltamivir included acute respiratory infection (66.7%), non-distinctive inflammatory reaction (51.3%), and influenza-like illness (2.7%). Influenza virus infection was confirmed by PCR in only 7%. Rhinovirus was the most frequent pathogen detected (14.9%). We discovered a wide range of adverse events but none occurred in >5%, and most were mild and of questionable causal relationship to oseltamivir administration.


This non-controlled retrospective analysis suggests that the preemptive use of oseltamivir for respiratory tract infections pending microbiological results is safe in LTRs.

PMID: 31172978 DOI: 10.3851/IMP3320

Keywords: Seasonal Influenza; Antivirals; Oseltamivir.


Published by

Giuseppe Michieli

I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum ( in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.